Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

William P. Docken MD  |  Issue: March 2013  |  

References

  1. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Disease patterns and tissue cytokines in giant cell arteritis. Arthritis Rheum. 1997;40:19-26.
  2. Barber HS. Myalgic syndrome with constitutional effects: Polymyalgia rheumatica. Ann Rheum Dis. 1957;16:854-862.
  3. Healey LA. Long-term follow-up of polymyalgia rheumatica: Evidence for synovitis. Semin Arthritis Rheum. 1984;13:322-328.
  4. Salvarani C,Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica: A disorder of extraarticular synovial structures? J Rheumatol. 1999;26:517-521.
  5. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943-954.
  6. Matteson EL. Clinical guidelines: Unraveling the tautology of polymyalgia rheumatica. Nat Rev Rheumatol. 2010;6:249-250.
  7. Docken WP. Polymyalgia rheumatica (PMR) can recur years after discontinuation of steroid therapy. Clin Exp Rheumatol. 2009;27:1(Suppl. 52):S25-S27.
  8. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454-1461.
  9. Ball EL, Walsh, SR, Tang TY, Gohil R, Clarke JMF. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg. 2010;97:1765-1771.
  10. Arida A, Kypianou M, Kanakiis M, Sfikakis. The diagnostic value of ultrasoasography-derived edema of the temporal artery in giant cell arteritis: A second meta-analysis. BMC Musculoskel Disord. 2010;11:44.
  11. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550-555.
  12. Hutchinson J. Diseases of the arteries. Arch Surg (London). 1889-90;1:323.
  13. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-1337.
  14. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306-3309.
  15. Narvaez J, Bernad B, Gomez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26 (Suppl. 49):S57-S62.
  16. Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischemic events in an Italian population based cohort of patients with giant cell arteritis. Rheumatology. 2009;48:250-253.
  17. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term follow-up. Arthritis Care Res. 2012;64:1079-1083.
  18. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology. 2012;51:151-156.
  19. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-flourodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006;55:131-137.
  20. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology. 2008;47:96-101.
  21. Nuenninghoff DM, Hunder GG, Christianson TJH, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum. 2003;48:3532-3537.
  22. Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: A population-based study. Medicine. 2004;83:335-341.
  23. Liang KP, Chowdhary VR, Michet CJ, et al. Noninfectious ascending aortitis: A case series of 64 patients. J Rheumatol. 2009;36:2290-2297.
  24. Schmidt J, Sunesen K, Kornum JB, Duhaut P, Thomsen RW. Predictors for pathologically confirmed aortitis after resection of the ascending aorta: A 12-year Danish nationwide population-based cross-sectional study. Arthritis Res Ther. 2011;13:R87.
  25. Stone JH, Khosroshahi A, Deshpande V, Stone JR. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res. 2010;62:316-322.
  26. Wang H, Smith RN, Spooner AE, et al. Giant cell aortitis of the ascending aorta without signs or symptoms of systemic vasculitis is associated with elevated risk of distal aortic events. Arthritis Rheum. 2012:64;317-319.
  27. Weyand CM, Younge BR, Goronzy JJ. IFN-γ IL-17–the two faces of T cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43-49.
  28. Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy proven giant cell arteritis. Br J Rheumatol.1997;36:251-254.
  29. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine. 2000;79:283-292.
  30. Liozon E, Herrmann F, Ly K, et al. Risk factors of visual loss in giant cell (temporal arteritis): A prospective study of 174 patients. Am J Med. 2001;111:211-217.
  31. Nesher G, Berkun Y, Mates M, et al. Risk factors of cranial ischemic complications in giant cell arteritis. Medicine. 2004;83:114-122.
  32. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633-639.
  33. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain,1988-1997. Clinical and epidemiologic aspects. Medicine.1999;78:292-308.

Related Articles

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

    Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

    Permanent Vision Loss in Late Giant Cell Arteritis

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

    Updates on Giant Cell Arteritis

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…